EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV ‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy

David B Cluck iD, Daniel B Chastain iD, Milena Murray iD, Spencer H Durham iD, Elias B Chahine iD, Caroline Derrick iD, Julie B Dumond iD, E Kelly Hester iD, Sarah B Jeter, Melissa D Johnson iD, Christin Kilcrease, Wesley D Kufel iD und 9 weitere

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.2914 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von David B Cluck und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, East Tennessee State University Bill Gatton College of Pharmacy, Johnson City, Tennessee, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Drug Resistance, Multiple, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pharmacotherapy Publications Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment options are currently limited for persons with HIV‐1 (PWH) who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1. Three agents have been approved by the U.S. Food and Drug Administration (FDA) since 2018, representing a significant advancement for this population: ibalizumab, fostemsavir, and lenacapavir. However, there is a paucity of recommendations endorsed by national and international guidelines describing the optimal use (e.g., selection and monitoring after initiation) of these novel antiretrovirals in this population. To address this gap, a modified Delphi technique was used to develop these consensus recommendations that establish a framework for initiating and managing ibalizumab, fostemsavir, or lenacapavir in PWH who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1. In addition, future areas of research are also identified and discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Drug Resistance, Multiple, ViralAnti-HIV AgentsHumansUnited StatesDelphi TechniqueAntibodies, MonoclonalOrganophosphatesPiperazines

Stichwörter der Autor:innen

HIVantiretroviralsanti‐HIV agentsattachment inhibitorcapsid inhibitordrug resistancepost‐attachment inhibitor

Substanzen

Anti-HIV AgentsibalizumabfostemsavirAntibodies, MonoclonalOrganophosphatesPiperazines

Autor:innen und Institutionen

  • Department of Pharmacy Practice, East Tennessee State University Bill Gatton College of Pharmacy, Johnson City, Tennessee, USA.
  • University of Georgia College of Pharmacy, Albany, Georgia, USA.
  • Midwestern University College of Pharmacy, Downers Grove, Illinois, USA.
  • Northwestern Medicine, Evanston, Illinois, USA.
  • Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy, Auburn, Alabama, USA.
  • Department of Pharmacy Practice, Palm Beach Atlantic University Gregory School of Pharmacy, West Palm Beach, Florida, USA.

ORCID-Profile: David B Cluck, Daniel B Chastain, Milena Murray, Spencer H Durham, Elias B Chahine, Caroline Derrick, Julie B Dumond, E Kelly Hester, Melissa D Johnson, Wesley D Kufel, Nimish Patel, Charlotte Bolch

Förderung

  • Pharmacotherapy Publications Inc.

Zitieren

APA

Cluck, D. B., Chastain, D. B., Murray, M., Durham, S. H., Chahine, E. B., Derrick, C., Dumond, J. B., Hester, E. K., Jeter, S. B., Johnson, M. D., Kilcrease, C., Kufel, W. D., Kwong, J., Ladak, A. F., Patel, N., Pérez, S. E., Poe, J. B., Bolch, C., Thomas, I., …, & Short, W. R. (2024). Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV ‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2914

Vancouver

Cluck DB, Chastain DB, Murray M, Durham SH, Chahine EB, Derrick C, et al. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV ‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.2914

BibTeX
@article{Cluck2024,
  author = {Cluck, David B and Chastain, Daniel B and Murray, Milena and Durham, Spencer H and Chahine, Elias B and Derrick, Caroline and Dumond, Julie B and Hester, E Kelly and Jeter, Sarah B and Johnson, Melissa D and Kilcrease, Christin and Kufel, Wesley D and Kwong, Jeffrey and Ladak, Amber F and Patel, Nimish and Pérez, Sarah E and Poe, Jonell B and Bolch, Charlotte and Thomas, Ian and Asiago-Reddy, Elizabeth and Short, William R},
  title = {Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV ‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.2914}
}
Kostenlos starten →